Cited by 849Angiogenesis and VEGF in CancerCancer Immunotherapy and BiomarkersLymphatic System and Diseases

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming

Open access

Tian, Lin, Goldstein, Amit, Wang, Hai, Ching Lo, Hin, Sun Kim, Ik, Welte, Thomas, Sheng, Kuanwei, Dobrolecki, Lacey E., Zhang, Xiaomei, Putluri, Nagireddy, Phung, Thuy L., Mani, Sendurai A., Stossi, Fabio, Sreekumar, Arun, Mancini, Michael A., Decker, William K., Zong, Chenghang, Lewis, Michael T., Zhang, Xiang H.-F.·2017·Nature

DOI 10.1038/nature21724PMC PMC5788037

Open this paper in CoChat — free account

Abstract

Blockade of angiogenesis can retard tumour growth, but may also paradoxically increase metastasis. This paradox may be resolved by vessel normalization, which involves increased pericyte coverage, improved tumour vessel perfusion, reduced vascular permeability, and consequently mitigated hypoxia. Although these processes alter tumour progression, their regulation is poorly understood. Here we show that type 1 T helper (T H 1) cells play a crucial role in vessel normalization. Bioinformatic analyses revealed that gene expression features related to vessel normalization correlate with immunostimulatory pathways, especially T lymphocyte infiltration or activity. To delineate the causal relationship, we used various mouse models with vessel normalization or T lymphocyte deficiencies. Although disruption of vessel normalization reduced T lymphocyte infiltration as expected, reciprocal depletion or inactivation of CD4+ T lymphocytes decreased vessel normalization, indicating a mutually regulatory loop. In addition, activation of CD4+ T lymphocytes by immune checkpoint blockade increased vessel normalization. T H 1 cells that secrete interferon-γ are a major population of cells associated with vessel normalization. Patient-derived xenograft tumours growing in immunodeficient mice exhibited enhanced hypoxia compared to the original tumours in immunocompetent humans, and hypoxia was reduced by adoptive T H 1 transfer. Our findings elucidate an unexpected role of T H 1 cells in vasculature and immune reprogramming. T H 1 cells may be a marker and a determinant of both immune checkpoint blockade and anti-angiogenesis efficacy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature21724

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Robust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
REVIGO summarizes and visualizes long lists of gene ontology terms
Supek, F., Bošnjak, M., Škunca, N., & Šmuc, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021800 · Cited by 6,264
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases
Xie, C., Mao, X., Huang, J., Ding, Y., Wu, J., Dong, S., Kong, L., Gao, G., Li, C., & Wei, L. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr483 · Cited by 5,078
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922

Show all 36 references

Sorted by citations

Items 601–700 of 849

[New Advances in the Treatment for Small Cell Lung Cancer].
Cui, X., Song, P., & Zhang, L. (2019) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2019.06.05 · Cited by 4
Integrated MRI–Immune–Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma
Mazzaschi, G., Olivari, A., Pavarani, A., Lagrasta, C. A. M., Frati, C., Madeddu, D., Lorusso, B., Dallasta, S., Tommasi, C., Musolino, A., et al. (2022) · Cancers · doi:10.3390/cancers14133249 · Cited by 4
Precise Therapeutic Benefits and Underlying Mechanisms of Anlotinib Combined With Checkpoint Immunotherapy in Advanced Non-Small-Cell Lung Cancer
Yi, X., Lu, X. J., Sun, Y., Liu, X., Wu, Y. Y., Rao, H., Que, Q. Y., Xiao, Q., Zhu, R., Feng, X. F., et al. (2022) · World Journal of Oncology · doi:10.14740/wjon1494 · Cited by 4
Volumetric imaging of optically cleared and fluorescently labeled animal tissue (VIOLA) for quantifying the 3D biodistribution of nanoparticles at cellular resolution in tumor tissue
Rakhilin, N., Yang, B., Spilker, M. E., Manzuk, L. K., Montgomery, M. K., Shin, E., Prashad, N., Hwang, J., Song, Y.-H., Loganzo, F., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.12.060 · Cited by 4
ADNP is associated with immune infiltration and radiosensitivity in hepatocellular carcinoma for predicting the prognosis
Wang, X., Peng, H., Zhang, G., Li, Z., Du, Z., Peng, B., & Cao, P. (2023) · BMC Medical Genomics · doi:10.1186/s12920-023-01592-x · Cited by 4
A robust vessel-labeling pipeline with high tissue clearing compatibility for 3D mapping of vascular networks
Deng, Y., Zhu, J., Liu, X., Dai, J., Yu, T., & Zhu, D. (2024) · iScience · doi:10.1016/j.isci.2024.109730 · Cited by 4
Vascular Normalization to Improve Treatment of COVID-19: Lessons from Treatment of Cancer
Munn, L. L., Stylianopoulos, T., Jain, N. K., Hardin, C. C., Khandekar, M. J., & Jain, R. K. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4750 · Cited by 4
Dual angiogenesis and PD-1 blockade in hepatocellular carcinoma
Caldéraro, J. (2020) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2019.10.37 · Cited by 4
Dihydroartemisinin restrains angiogenesis through the TNF-α pathway to enhance the efficacy of anti-PD-1 immunotherapy in breast cancer
Zou, M., Gong, Y., Zeng, J., Zhang, X., Guo, X., Hua, J., Chen, Z., Lin, L. C., & Wu, F. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152171 · Cited by 4
Self-citation
NO‐Driven Janus Nanomotor Enhances T‐Cell Infiltration by Reconstructing Tumor‐Associated Blood and Lymphatic Vessels
Ma, Q., Fu, S., Xia, Y., Gao, S., Xia, Z., Gu, P., Yuan, S., Liu, J., Liang, S., Li, N., et al. (2025) · Advanced Science · doi:10.1002/advs.202512090 · Cited by 3
Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): an open-label, single-arm, phase II trial
Wang, Z., Qin, B., Ye, C.-Y., Wang, M., Yuan, L., Yao, H., Jiao, X., Liu, K., Zhou, W., Qin, W., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02383-9 · Cited by 3
PD-1 inhibitor improves radiosensitivity by tumor vessel normalization
Hao, S., Ai, D., Wang, Q., Zhang, X., Ma, X., Tseng, I., Shen, J., Chen, Y., Liu, Q., Deng, J., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03315-8 · Cited by 3
Self-citation
CXC Chemokine‐Driven Vascular Reprogramming: Modulating Tumor Vasculature to Boost Therapeutic Response
Chen, H., Huang, Y., Wu, Yi, Z., Li, Y., Yang, Z., Zhang, F., & Li, C. (2026) · Advanced Science · doi:10.1002/advs.202523331 · Cited by 3
Tumor Anti‐Angiogenesis Therapy and Its Influence on Immune Cell Function in the Tumor Microenvironment
Tang, Y., Ding, Y., Wang, L., Yang, Y., Han, Y., Zhou, P., Qu, H., Deng, K., & Xia, J. (2026) · Cancer Medicine · doi:10.1002/cam4.71769 · Cited by 3
CD4 + T cells impair tumor growth through IL-3 and TNF-dependent vascular damage
Lian, Q., Nie, J., Singh, J., Chen, Q., Matta, J. L., Chan, W., Balmaceno-Criss, M., Vacchio, M. S., Yu, W., Clark, A. D., et al. (2026) · Science · doi:10.1126/science.ads7910 · Cited by 5
Complete Remission of Ovarian Clear Cell Carcinoma Achieved after Pseudoprogression During PD-1 Inhibitor Therapy
Ma, B., Zhao, L., Zhang, Y., Zhang, F., & Gao, Q. (2022) · Immunotherapy · doi:10.2217/imt-2021-0328 · Cited by 3
Comparative prognostic value of tumor volume in IOIO and IOTKI treatment for metastatic renal cancer
Hara, T., Ueki, H., Okamura, Y., Bando, Y., Suzuki, K., Terakawa, T., Chiba, K., Hyodo, Y., Teishima, J., & Miyake, H. (2024) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2024.10.015 · Cited by 3
Overexpression of FOS enhances the malignant potential of eutopic endometrial stromal cells in patients with endometriosis‑associated ovarian cancer
Chen, J., He, K., Li, X., Wang, M., Yang, Z., Wang, Z., Wang, K., Jiang, W., Zhao, L., & Cui, M. (2025) · Oncology Reports · doi:10.3892/or.2025.8878 · Cited by 3
The role of tumor microenvironment in lenvatinib resistance of hepatocellular carcinoma
Jiang, Y., Huang, Y., Hu, X., Chen, R., Chen, R., & Xu, X. (2025) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2025.102642 · Cited by 3
Elevated pretreatment neutrophil-to-lymphocyte ratio indicate low survival rate in apatinib-treated patients with non-small cell lung cancer: A STROBE-compliant article
Wan, Y.-N., Chen, H., Liu, X.-F., Gu, W., & Lu, Y.-Y. (2022) · Medicine · doi:10.1097/md.0000000000032043 · Cited by 3
Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer
Fu, S., Huang, H., Shang, K., Tu, G.-J., Zhong, P., Li, S., Zhu, X., Peng, S., Liu, Y., Lu, Z., et al. (2023) · Future Oncology · doi:10.2217/fon-2022-0861 · Cited by 3
Role of miR-301b-3p/5p in breast cancer: A study based on the cancer GenomeAtlas program (TCGA) and bioinformatics analysis
Zhou, Q., Wang, F., Sun, E., Liu, X., & Lu, C. (2023) · Non-coding RNA Research · doi:10.1016/j.ncrna.2023.08.002 · Cited by 3
Pulmonary blastoma is successfully treated with immunotherapy and targeted therapy
Chen, Y., Chen, H., Yu, R., Zeng, X., Tian, D., Pu, Q., & Liu, Y. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107476 · Cited by 3
Real-world efficacy, safety data and predictive clinical parameters for treatment outcomes in advanced soft tissue sarcoma treated with combined immunotherapy and antiangiogenic therapy
Li, S., Sun, Q., Bai, R., Wang, Y., Wang, H. Z., Chen, H., & Dong, Y. (2024) · BMC Cancer · doi:10.1186/s12885-024-12810-9 · Cited by 3
Self-citation
Efficacy and safety of concurrent programmed cell death protein 1 inhibitor and definitive radiotherapy with immunonutrition support in esophageal squamous cell cancer: a phase II multicenter clinical trial
Yuan, Y., Luo, S., Wang, X., Zheng, Z., Qi, Q., Wang, Y., Chen, M., Yang, H., Gu, P., Du, Q., et al. (2025) · Radiation Oncology · doi:10.1186/s13014-025-02604-z · Cited by 3
Anti-tumour effect of in situ vaccines combined with VEGFR inhibitors in the treatment of metastatic cervical cancer
Liu, L., Cai, L., Du, X., Zhao, J., Zhao, Y., Zou, C., Yu, S., Zhang, C., Ye, P., Su, X., et al. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108302 · Cited by 3
The use of cognitive psychology-based human-computer interaction tax system in ceramic industry tax collection and management and economic development of Jingdezhen city
Mingqing, J. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.944924 · Cited by 3
Treatment with camrelizumab plus tyrosine kinase inhibitors with or without TACE for intermediate-advanced hepatocellular carcinoma: a clinical efficacy and safety study
Yin, Y., Li, Y., Xiong, Y., Xian, Y., Meng, C., He, K., He, Y., & Li, J. (2023) · ONCOLOGIE · doi:10.1515/oncologie-2022-1019 · Cited by 3
Screening for therapeutic targets of tumor angiogenesis signatures in 31 cancer types and potential insights
Peng, J., Xu, H., Chen, Y., Wang, W., Zhu, L., Shao, Y., & Wang, J. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.11.095 · Cited by 3
The effect of PHD inhibitor on tumor microenvironment and tumor immune response
Matsunaga, S., & Tomita, S. (2019) · Folia Pharmacologica Japonica · doi:10.1254/fpj.19119 · Cited by 3
Bioinformatics analysis of the primary molecular mechanism in lymphatic vascular space invasion and parametrial invasion of cervical cancerPreprint
He, X.-M., Cui, Y.-Q., He, D.-L., Zhao, J.-X., Zhao, L., & Huang, G. (2022) · Research Square · doi:10.21203/rs.3.rs-2012413/v1 · Cited by 3
A tumor microenvironment-based classification of gastric cancer for more effective diagnosis and treatmentPreprint
Duda, D. G., Dima, S., Sorop, A., Kitahara, S., Setia, N., Chivu‐Economescu, M., Matei, L., Herlea, V., Pechianu, N., Inomata, T., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3089359/v1 · Cited by 3
Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era
Zheng, J., Zheng, Z., Zhang, T., Chen, X., Pang, Q., Wang, P., Yan, C., & Zhang, W. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2423009 · Cited by 2
An early-stage 3D fibroblast-featured tumor model mimics the gene expression of the naïve tumor microenvironment, including genes involved in cancer progression and drug resistance
Costabile, F., George, S. S., Facciabene, A., Filaci, G., & Mastrogiacomo, M. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1572315 · Cited by 2
Patient-derived geometry-integrated multiphysics framework: Computational optimization of immunotherapeutic nanoparticle delivery via tumor microenvironment reprogramming in prostate cancer
Mirala, F., & Soltani, M. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.111388 · Cited by 2
Effectiveness and mechanisms of lymphocytes at different time points in predicting consolidation immunotherapy following adaptive chemoradiotherapy in locally advanced non-small cell lung cancer
Sun, Z. W., Duan, J., Zhang, Z., Chen, M., Zhou, D., Hou, L., Gu, P., Zhu, J., Yang, H., & Zhou, S. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1683430 · Cited by 2
Dissecting the aberrant vasculature of glioblastoma: mechanisms and therapeutic targets
Li, Y., Du, Y., Guan, F., Li, X., Cui, S., Gao, W., Long, X., & Wu, M. (2026) · Cancer and Metastasis Reviews · doi:10.1007/s10555-026-10319-0 · Cited by 3
FLASH radiotherapy and immunotherapy synergy: mechanisms, strategies, and clinical translation prospects
Liu, Q., Zeng, X., He, Y., Zhou, L., Tang, Y., Liu, S., Wang, X., Shen, S., Ji, J., Liu, Z., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1788149 · Cited by 2
Targeting Tumor Stroma: Current Challenges and Future Directions
Wang, S., Hu, H., Zeng, W., Qin, L., Chen, X., Liao, Z., Liu, F., & Zhang, Z. (2026) · MedComm · doi:10.1002/mco2.70763 · Cited by 2
Modeling blood–brain barrier–glioblastoma interactions: implications for chemoresistance and therapeutic targeting
Ammar, M. A. N., Dobiasová, S., Salaroglio, I. C., Hmissa, S., Missaoui, N., & Riganti, C. (2026) · Fluids and Barriers of the CNS · doi:10.1186/s12987-026-00816-3 · Cited by 2
NF1 loss in estrogen receptor-positive breast cancer induces osteoclast formation and immunosuppression to promote bone metastasis
Zhao, Z., Zheng, Z.-Y., Lei, J. T., Baik, M. J., Wu, Y.-H., Somes, L. K., Paternina, A. F. M., Harb, O. A., Chang, O. A., Liu, F., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218636 · Cited by 3
Self-citation
Integrating Seropharmacology, Network Pharmacology, and Single‐Cell Transcriptomics to Decipher the Dual Anti‐Tumor Mechanisms of Astragalus– Curcuma zedoaria in Lung Squamous Cell Carcinoma
Yu, L., Dong, X., Yang, Q., & 窦永起 (2026) · Biomedical Chromatography · doi:10.1002/bmc.70482 · Cited by 2
CAR-T and TIL therapies in solid tumors: barriers, clinical lessons, and convergent solutions
Bach, D., Hoang, V. H., Pham, T. V., Huong, & Nguyen, D. D. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04425-w · Cited by 2
Combination of pembrolizumab and axitinib: a new gold standard in the first-line therapy for metastatic clear-cell renal-cell carcinoma?
Gafanov, R. A., Dzidzaria, A. G., Борисович, К. И., & Фастовец, С. В. (2020) · Cancer Urology · doi:10.17650/1726-9776-2020-16-3-29-37 · Cited by 2
A review on Biomarkers for predicting radioresistance and role of natural radiosensitizers in Triple-Negative Breast Cancer
Mehta, D., Brahmbhatt, J., Bhadresha, K. P., & Rawal, R. (2023) · International Journal of Pharmaceutical Sciences and Drug Research · doi:10.25004/ijpsdr.2023.150418 · Cited by 2
Clinical evaluation of sintilimab in conjunction with bevacizumab for advanced colorectal cancer with microsatellite stable-type after failure of first-line therapy
Wang, L., Diao, Y.-Z., Ma, X., Luo, Y., Guo, Q., & Chen, X.-Q. (2024) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v16.i10.3277 · Cited by 2
A Three-agent Regimen for Triple Negative Breast Cancer Treatment
Wang, S., Huang, C., Zhu, Y., Wang, M., Wang, W., Liu, C., & Su, W. (2025) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/0115748928350267250105153944 · Cited by 2
A Machine Learning‐Optimized Immunogenic Cell Death Signature Reveals Tumor Immunogenicity and the Immunotherapy Response of Pancancer
Qiu, L., Huang, D., Zhang, Y., Zhou, Y., Luo, M., Zhang, C., Huang, Y., Zou, M., Lu, W., Liu, H., et al. (2025) · MedComm – Future Medicine · doi:10.1002/mef2.70035 · Cited by 2
Anti-VEGFR Therapy as a Partner for Immune-Based Therapy Approaches in HCC
Shigeta, K., Hato, T., Chen, Y., & Duda, D. G. (2017) · Springer eBooks · doi:10.1007/978-3-319-64958-0_6 · Cited by 2
European Network of Breast Development and Cancer turned 10 years: a growing family of mammary gland researchers
Koledova, Z. S., Howard, B. A., Englund, J. I., Bach, K., Bentires‐Alj, M., & González‐Suárez, E. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1032-9 · Cited by 2
Methods in Computational Biology
Carlson, R. P., & Sauro, H. M. (2019) · MDPI eBooks · doi:10.3390/books978-3-03921-164-7 · Cited by 2
[Research Progress of Anti-angiogenic Agents Combined with Immunotherapy in Patients with Advanced Non-small Cell Lung Cancer].
Wang, J., Peng, W., Jiang, M., & Wu, L. (2021) · PubMed Central · doi:10.3779/j.issn.1009-3419.2021.101.05 · Cited by 2
Clinical efficacy of pseudomonas aeruginosa injection combined with endostar in the treatment of malignant pleural effusion: a randomized trial.
Cheng, J., Zhao, X., Li, Z., Yang, M., Zhang, Y., Liu, Y., & Cao, C. (2023) · PubMed Central · Cited by 2
Bioinformatics Analysis and Experimental Verification Define Different Angiogenesis Subtypes in Endometrial Carcinoma and Identify a Prognostic Signature
Zhang, Q., Yao, Y., Yu, Z., Zhou, T., Zhang, Q., Li, H., Zhang, J., Wei, S., Zhang, T., & Wang, H. (2024) · ACS Omega · doi:10.1021/acsomega.4c03034 · Cited by 2
Self-citation
Evaluating the efficacy and safety of trebananib in treating ovarian cancer and non-ovarian cancer patients: a meta-analysis and systematic review
Zhang, J., Su, J., Zhou, Y., & Lu, J. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2377793 · Cited by 2
Cancer Angiogenesis and Its Master Regulator Perlecan
Kovalszky, I., Váncza, L., Reszegi, A., Tátrai, P., & Baghy, K. (2022) · Biology of extracellular matrix · doi:10.1007/978-3-030-99708-3_15 · Cited by 2
Premetastatic niche and tumor-related leukocytosis: a close relationship that cannot be ignored in uterine cancer patients
Mabuchi, S., Sasano, T., & Komura, N. (2018) · Oncotarget · doi:10.18632/oncotarget.26425 · Cited by 2
Anticancer immunotherapies transition postcapillary venules into high-endothelial venules that generate TCF1+ T lymphocyte niches through a feed-forward loopPreprint
Hua, Y.-C., Vella, G., Rambow, F., Allen, E., Martinez, A. A., Duhamel, M., Junius, S., Smeets, A., Nittner, D., Laoui, D., et al. (2021) · bioRxiv · doi:10.1101/2021.12.24.474088 · Cited by 3
Tumor Angiogenesis
Heymach, J. V., Zurita‐Saavedra, A., Kopetz, S., Cascone, T., Nilsson, M. B., & Guijarro, I. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm017.pub2 · Cited by 2
A targetable developmental program co-regulates angiogenesis and immune evasionPreprint
Berico, P., Yanke, A. F., Vand-Rajabpour, F., Do, C., Wilmer, I. S., Sakellaropoulos, T., Delclaux, I., Stagnitta, R., Vázquez‐Cruz, M. E., Osman, I., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.21.628442 · Cited by 2
Antiangiogenic drugs as chemosensitizer in melanoma
Quaresmini, D., & Guida, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90190-1.00003-2 · Cited by 1
Anti-Angiogenic Agents Combined with Immunotherapy for Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Lin, H., Ma, C., Zhong, A., Zang, H., Chen, W., Li, L., Le, Y., & Xie, Q. (2023) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207326666230808112656 · Cited by 1
Metastasis Models: Thermodynamics and Complexity
Guerra, A., Betancourt-Mar, J. A., Llanos-Pérez, J. A., Mansilla, R., & Nieto-Villar, J. M. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3577-3_4 · Cited by 1
PDGFRβ-Antagonistic Affibody-Mediated Tumor-Targeted Tumor Necrosis Factor-Alpha for Enhanced Radiotherapy in Lung Cancer
Tang, X., Chen, J., Zhao, Z., Liu, J., Yu, R., Zhao, K., Wang, F., Li, Y., Tian, B., Yuan, D., et al. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00869 · Cited by 1
Anlotinib combined with tislelizumab in the treatment of primary small cell neuroendocrine carcinoma of the prostate: a case report and literature review
Xin, F., Zheng, Z., Zhao, Z.-Y., Ren, D., Wang, S., Ye, S.-J., Liang, L.-C., Li, D., Jia, X., & Ma, Q. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1510069 · Cited by 1
Famitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket study
Ai, L., Li, Q., Zhang, S., Dong, Y. J., Yang, M., Li, J., Yueyin, P., Yuan, Y., Yi, S., Wang, J., et al. (2025) · The Innovation · doi:10.1016/j.xinn.2024.100745 · Cited by 1
Self-citation
Recombinant human‑endostatin combined with sintilimab and chemotherapy in first‑line treatment of locally advanced or metastatic esophageal squamous cell carcinoma
Cui, S., Fan, L., Sun, X., Cai, Y., Wang, T., Li, P., Wang, R., & Liu, L. (2025) · Oncology Letters · doi:10.3892/ol.2025.14990 · Cited by 1
Impact of baseline glucocorticoid use on the efficacy of immunotherapy combined with intracranial radiotherapy in NSCLC patients with brain metastases
Xiong, J., Shi, W., Huang, Y., Jian, H., Xu, Z., Tang, H., Huang, S., Yang, Z., & Peng, Y. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf158 · Cited by 1
Roles of the phagocytosis checkpoint in radiotherapy
Kui, Y., Tong, F., Zhang, R., Wang, J., & Dong, X. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07921-5 · Cited by 1
Effects of anlotinib combined with camrelizumab and chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma on tumor immune microenvironment
Xu, M., Liu, Y., Kuang, X., Liao, X., & Zhao, X. (2025) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-2025-30 · Cited by 1
A tumor microenvironment-based classification of gastric cancer for more effective diagnosis and treatment
Dima, S., Sorop, A., Kitahara, S., Setia, N., Chivu‐Economescu, M., Matei, L., Herlea, V., Pechianu, N., Inomata, T., Matsui, A., et al. (2025) · Surgical Oncology · doi:10.1016/j.suronc.2025.102298 · Cited by 1
Tumor Microcirculation: Abnormalities and Normalization
Fukumura, D. (2025) · Physiology in health and disease · doi:10.1007/978-3-031-99609-2_13 · Cited by 1
Efficacy and safety of radiotherapy in first-line treatment for de novo advanced esophageal cancer in the era of immunochemotherapy: a systematic review and meta-analysis
Zeng, H., Wu, Y., Wang, X., Bai, H., Yan, C., Zhang, W., & Wang, Q. (2025) · BMC Cancer · doi:10.1186/s12885-025-15420-1 · Cited by 1
Radiotherapy dose may not affect prognosis in ESCC patients receiving first-line chemoradiotherapy-immunotherapy: A multicenter retrospective study
Wen, J., Liu, X., Xu, Y., Lin, Z., Hou, M., Gui, Y., Cao, J., Hou, Q., Lv, J., Wang, L., et al. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04261-3 · Cited by 1
Endothelial PDLIM5 promotes tip cell filopodia formation and tumor angiogenesis by regulating ACTN1/ACTN4-dependent actin bundling
Xu, Z., Shi, Y., Yang, Y., Tang, B., Zhao, J., Xiao, M., Jiang, S., Jiang, X., Maihemuti, N., Zhang, K., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68765-x · Cited by 1
Self-citation
A Targetable Developmental Program Coregulates Angiogenesis and Immune Evasion in Melanoma
Berico, P., Yanke, A. F., Vand-Rajabpour, F., Do, C., Wilmer, I. S., Delclaux, I., Muijlwijk, T., Stagnitta, R., Vázquez‐Cruz, M. E., Sakellaropoulos, T., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1853 · Cited by 2
Consequences of the perivascular niche remodeling for tumoricidal T-cell trafficking into metastasis of ovarian cancer
Winkler, M., Malhotra, N., Mistarz, A., Wang, S., Hutson, A. D., Gambotto, A. A., Abrams, S. I., Singh, P. K., Liu, S., Odunsi, K. O., et al. (2026) · ImmunoHorizons · doi:10.1093/immhor/vlaf084 · Cited by 2
VEGF-TKI Outcomes in Metastatic Renal Cell Carcinoma According to Prior Immune Checkpoint Inhibitor or VEGF-TKI: A Scoping Review and Exploratory Analysis
Nally, E., Jovaisaite, A., Membribes, S. C., Priyadarshini, G., Graham, C., MacDonald, A., Jackson‐Spence, F., Szabados, B. E., & Powles, T. B. (2026) · Cancers · doi:10.3390/cancers18050807 · Cited by 1
Soluble cytokines and chemokines in NSCLC: drivers of immune evasion and angiogenesis
Yang, L., Fan, Z., Wang, Z., & Zhou, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1699065 · Cited by 1
scResponse: A Rank‐Based Method for Identifying Cell States That Contribute to Immunotherapy Response by Single‐Cell Data
Dong, Q., Huang, H., Wang, Y., Jiang, B., Chen, Y., Xu, H., Ren, J., Guo, S., Li, T., Zhang, M., et al. (2026) · Advanced Science · doi:10.1002/advs.202524397 · Cited by 1
Harnessing Ultrasound for Tumor Vascular Targeting: From Mechanistic Insights to Clinical Monitoring and Therapeutic Applications
Lei, L., Yang, H., Du, M., & Chen, Y. (2026) · BIO Integration · doi:10.15212/bioi-2025-0117 · Cited by 1
Sonoimmunology in cancer therapy: expanding crosstalk among ultrasound-materials-immune system
Liu, Z., Wu, P., & Yuan, L. (2026) · Materials & Design · doi:10.1016/j.matdes.2026.116179 · Cited by 1
The vascular niche: an orchestrator of the spatiotemporal dynamics of distant metastasis
Miao, Q., Chen, R., Zhang, D.-M., Zhang, J.-Q., & Chen, M.-F. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01820-x · Cited by 1
An overview of current research on exercise interventions in aging and aging-related disease
Jain, A., Johnston, C., Zhang, Y., Oh, J., Tsung, C., Kent, E., & Zhang, H. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1832962 · Cited by 2
CEUS features-based nomogram for predicting early recurrence (ER) of microvascular invasion-negative hepatocellular carcinoma
Shu, Q., Liu, Y., Pang, C., Wang, Z. R., Tian, X., Wang, S., Yan, X., Liang, P., Yu, J., & Yu, X. (2026) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_2174_25 · Cited by 1
Innate immunity in tumors: From mechanisms to therapeutics
Hu, Y., Wang, X., Ma, H., & Zheng, X. B. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004116 · Cited by 1
Impact of PD ‐1 Inhibitor Timing Relative to Locoregional Therapy on Outcomes in uHCC Treated With Lenvatinib‐Based Triple Therapy
He, J., Chen, J., Yu, B., Wei, F., Liu, W., 黃培書, Wu, S., You, X., Chen, Z., Lin, Z., et al. (2026) · Liver International · doi:10.1111/liv.70847 · Cited by 1
Clinical strategies to inhibit tumor vascularization
Harris, A. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819494-2.00009-2 · Cited by 1
COLORECTAL MOLECULAR SUBTYPES – PROGRESS OR DEADLOCK?
Fedyanin, M. Y., Ignatova, E. O., & Tryakin, А. А. (2021) · Practical oncology · doi:10.31917/2201072 · Cited by 1
Durable clinical response to immunotherapy in EGFR-mutated lung adenocarcinoma with squamous cell carcinoma transformation and high expression of PD-L1 after resistance development: A case report
Peng, Z., & Xu, Y. (2022) · Current Problems in Cancer Case Reports · doi:10.1016/j.cpccr.2022.100199 · Cited by 1
The surge of HBsAb level in a HBsAg-negative ES-SCLC patient after anlotinib plus atezolizumab treatment: A case report
Chen, G., Tian, T., & Cai, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1103512 · Cited by 1
Immune Checkpoint Inhibitors and Anti-Angiogenic Therapy for Cancer
Solimando, A. G., & Ribatti, D. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_163-1 · Cited by 1
Nutrient Sensing in Macrophages Linked to Reorganized Tumor Vasculature
Chan, H. L., & Zhang, X. H.-F. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0201 · Cited by 1
Self-citation
ANGPT1 promotes M1 macrophage polarization and inhibits lung adenocarcinoma progression by inhibiting the TGF-β signalling pathway
Liu, G., & Zhang, H. (2024) · General Physiology and Biophysics · doi:10.4149/gpb_2024001 · Cited by 1
Dynamic processes of positive/negative immune-vascular crosstalk loop via functional MRI-guided monitor
Zhang, R., Jin, T., Zhang, Y., Sui, X., Wu, S., Wu, Y., Hao, D., Yao, Z., Yu, Z., Liu, X., et al. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.152674 · Cited by 1
Three-dimensional characteristics of T cells and vasculature in the development of mouse esophageal cancer
Bi, S., Wu, Y., Ding, N., Zhou, Y., Liu, H., Weng, Y., Song, Q., Zhang, L., Cheng, M. Y., Cui, H., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111380 · Cited by 1
Breast cancer stroma and its components: Implication in diagnostic and therapeutic
Sharma, R., Kumar, P., Kumar, V., Singh, S. P., Garg, V. K., Okpala, C. O. R., Thakur, S., Singh, H., Nim, D. K., Buttar, H. S., et al. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24838-2.00004-5 · Cited by 1
Donafenib versus sorafenib in triple therapy for unresectable hepatocellular carcinoma: a propensity score-matched multicenter analysis
Wen, Y., Zhou, S., Xu, Y., Zhang, C., Feng, Z., Song, Y., Ding, B., Peng, C., Tan, H., Wang, C., et al. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-03767-5 · Cited by 1
Anlotinib plus toripalimab as a first-line treatment in patients with advanced gastric cancer and performance status 2: the phase II APICAL-GC trial
Liu, K., Qin, B., Chen, S., Zhong, X., Duan, X.-P., Wu, Y., Wang, Z., Ling, Y., Sun, L., Ye, C.-Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60317-z · Cited by 1
Tumor Genotype Is Shaping Immunophenotype and Responses to Immune Checkpoint Inhibitors in Solid Tumors
Marcelo-Lewis, K. L., Moorthy, S., & Ileana-Dumbrava, E. (2020) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-20-6 · Cited by 1

Authors: Tian, L., Goldstein, A., Wang, H., Ching Lo, H., Sun Kim, I., Welte, T., Sheng, K., Dobrolecki, L. E., Zhang, X., Putluri, N., Phung, T. L., Mani, S. A., Stossi, F., Sreekumar, A., Mancini, M. A., Decker, W. K., Zong, C., Lewis, M. T., & Zhang, X. H.-F.
Affiliations: Baylor College of Medicine (US)
The University of Texas MD Anderson Cancer Center (US)
Corresponding author: Zhang, Xiaomei
Zhang, Xiang H.-F.
ORCID: Tian, Lin
Goldstein, Amit
Wang, Hai
Welte, Thomas
Sheng, Kuanwei
Dobrolecki, Lacey E.
Zhang, Xiaomei
Putluri, Nagireddy
Phung, Thuy L.
Mani, Sendurai A.
Stossi, Fabio
Sreekumar, Arun
Mancini, Michael A.
Decker, William K.
Zong, Chenghang
Lewis, Michael T.
Zhang, Xiang H.-F.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2017-04
Volume: 544
Issue: 7649
Pages: 250-254
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature21724
PMC: PMC5788037
OpenAlex: W2601414401
Cited by: 841
References: 36
Citations by year: 2026: 88 · 2025: 98 · 2024: 98 · 2023: 100 · 2022: 92 · 2021: 129 · 2020: 97 · 2019: 63 · 2018: 51 · 2017: 25
FWCI: 26.46
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: National Institutes of Health (1s10od016167-01)
National Cancer Institute (R00CA151293, R01CA220297, K99CA151293, R21CA185516, U01CA179674, R01CA183878, P30CA125123)
National Institute of Allergy and Infectious Diseases (P30AI036211, R01AI127387)
National Institute of Diabetes and Digestive and Kidney Diseases (P30DK056338)
National Center for Research Resources (S10RR024574)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
Keywords: tumor immunosuppression, pericyte coverage, tumor hypoxia, CD4+ T cells, Th1 cells, interferon-gamma, immune checkpoint blockade, anti-angiogenic therapy, T cell infiltration, endothelial cells, tumor vasculature, patient-derived xenografts, cancer immunotherapy
MeSH terms: Animals, Capillary Permeability, Female, Humans, Interferon-gamma, Mice, Inbred BALB C, Mice, Inbred C57BL, Neoplasms, Neovascularization, Pathologic, Prognosis, CD4-Positive T-Lymphocytes, Cell Hypoxia, Lymphocytes, Tumor-Infiltrating, Th1 Cells, Neovascularization, Physiologic, Adoptive Transfer, Pericytes, Xenograft Model Antitumor Assays, Endothelial Cells, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks